Couchoud C, Pouteil-Noble C, Colon S, Touraine J L
Transplantation Unit, E. Herriot Hospital, Lyon, France.
Transplantation. 1995 May 15;59(9):1275-9.
The exact incidence of recurrence of membranous nephropathy (MN) after renal transplantation is not well documented because of the limited number of series involving a small number of patients. The aim of this study was to assess the incidence of MN recurrence in our population of renal transplant patients, to identify the risk factors associated with the recurrence, and to analyze the influence of the recurrence on graft and patient survival rates. The recurrence was defined as biopsy-proven MN on the renal graft in a patient whose original disease was MN. Among 1614 consecutive renal transplantations performed from January 1, 1980, to June 1, 1993, the incidence of recurrence was 26.3%, i.e., 5 recurrences out of 19 transplantations. We were unable to show pretransplant epidemiological, immunological, and therapeutic factors associated with recurrence. The HLA DR3 allele was present in 2 patients with recurrence (40%), compared with 3 patients without recurrence (21.4%). The early use of cyclosporine was not associated with a decreased prevalence of MN recurrence. Graft survival was not influenced by the recurrence. Three lymphomas were observed in the 19 transplanted patients with MN as causal nephropathy.
由于涉及患者数量较少的系列研究有限,肾移植后膜性肾病(MN)复发的确切发生率尚无充分记录。本研究的目的是评估我们肾移植患者群体中MN复发的发生率,确定与复发相关的危险因素,并分析复发对移植物和患者存活率的影响。复发定义为原发病为MN的患者肾移植活检证实为MN。在1980年1月1日至1993年6月1日期间进行的1614例连续肾移植中,复发率为26.3%,即19例移植中有5例复发。我们未能发现与复发相关的移植前流行病学、免疫学和治疗因素。复发的2例患者(40%)存在HLA DR3等位基因,未复发的3例患者中该等位基因的存在率为21.4%。早期使用环孢素与MN复发率降低无关。移植物存活不受复发影响。在19例以MN为病因肾病的移植患者中观察到3例淋巴瘤。